Repurposing of rutin for the inhibition of norovirus replication
- 293 Downloads
Drug repurposing is a strategy employed to circumvent some of the bottlenecks involved in drug development, such as the cost and time needed for developing new molecular entities. Noroviruses cause recurrent epidemics and sporadic outbreaks of gastroenteritis associated with significant mortality and economic costs, but no treatment has been approved to date. Herein, a library of molecules previously used in humans was screened to find compounds with anti-noroviral activity. Antiviral testing for four selected compounds against murine norovirus infection revealed that rutin has anti-murine norovirus activity in cell-based assays.
KeywordsRutin Suramin Antiviral Efficacy Kasugamycin Rutinose
This work was supported by Defense Advanced Research Projects Agency (DARPA) Contract HR0011-11-C-0093. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors thank Audrey E. Fischer, Joshua T. Wolfe, Jeffrey S. Lin, and Andrew B. Feldman from the Applied Physics Laboratory of Johns Hopkins University (MD, USA) for helpful discussions. We also thank Xiaoyan Lin and Emma Winkler at Indiana University for performing the RdRp assays, and David George at Kansas State University for performing the protease assay. The computations performed herein were run on the Odyssey cluster supported by the FAS Division of Science, Research Computing Group at Harvard University.
- 8.Dhanak D, Duffy KJ, Johnston VK, Lin-Goerke J, Darcy M, Shaw AN, Gu B, Silverman C, Gates AT, Nonnemacher MR, Earnshaw DL, Casper DJ, Kaura A, Baker A, Greenwood C, Gutshall LL, Maley D, DelVecchio A, Macarron R, Hofmann GA, Alnoah Z, Cheng HY, Chan G, Khandekar S, Keenan RM, Sarisky RT (2002) Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J Biol Chem 277:38322–38327CrossRefPubMedGoogle Scholar
- 11.Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47:1739–1749CrossRefPubMedGoogle Scholar
- 34.Reuters T (2012) Knowledge-based drug repositioning to drive R&D productivity. White paper. Thompson ReutersGoogle Scholar
- 37.Rocha-Pereira J, Jochmans D, Debing Y, Verbeken E, Nascimento MS, Neyts J (2013) The viral polymerase inhibitor 2’-C-methylcytidine inhibits Norwalk virus replication and protects against norovirus-induced diarrhea and mortality in a mouse model. J Virol 87:11798–11805PubMedCentralCrossRefPubMedGoogle Scholar
- 43.Treanor JJ, Atmar RL, Frey SE, Gormley R, Chen WH, Ferreira J, Goodwin R, Borkowski A, Clemens R, Mendelman PM (2014) A novel intramuscular bivalent norovirus virus-like particle vaccine candidate-reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults. J Infect Dis 210:1763–1771CrossRefPubMedGoogle Scholar
- 44.Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N, National Surgical Adjuvant B, Bowel P (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2727–2741CrossRefPubMedGoogle Scholar
- 48.Yunus MA, Lin X, Bailey D, Karakasiliotis I, Chaudhry Y, Vashist S, Zhang G, Thorne L, Kao CC, Goodfellow I (2015) The murine norovirus core subgenomic RNA promoter consists of a stable stem-loop that can direct accurate initiation of RNA synthesis. J Virol 89:1218–1229PubMedCentralCrossRefPubMedGoogle Scholar